A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer ['COMPLETE' study: Comparison of Lapatinib Efficacy vs. Trastuzumab, Each with a Taxane in First Line Metastatic Breast Cancer].

Trial Profile

A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer ['COMPLETE' study: Comparison of Lapatinib Efficacy vs. Trastuzumab, Each with a Taxane in First Line Metastatic Breast Cancer].

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Docetaxel; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms COMPLETE
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 23 Apr 2017 Planned End Date changed from 21 Dec 2017 to 31 Dec 2019.
    • 07 Mar 2017 Planned End Date changed from 1 Dec 2016 to 21 dec 17.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top